ATTENTION

CANCER RESEARCHERS:

Receive current bibliographic data on the subject of your choice...with

Research ALERT
YOUR WEEKLY CUSTOMIZED ALERTING SERVICE

Keep on top of the weekly journal literature of your field...without spending the time and money it would take to do it yourself. With Research Alert™, the article alerting service that does the work for you.

Research Alert searches the contents of 8,000 leading international science, technical and social sciences journals — each week, item-by-item — to give you a full bibliographic report on the most current articles that are important to you.

Simply select the Research Alert Topic that reflects your research interests. There are over two-hundred topics to choose from — from cancer detection and diagnosis, to cell growth and differentiation, to breast cancer.

Or order a Customized Research Alert, the unique Research Alert report that is personally and confidentially developed for you to meet your specific, individual interests. Either way, you'll get the exact information you need — and nothing else — on a list you can scan in a matter of minutes.

For more information about Research Alert, call toll-free: 800-523-1850, extension 1453, operator C333. Or write to the address below.

Institute for Scientific Information
3501 Market Street, Philadelphia, PA 19104 USA
Telephone: 215-386-0100, extension 1453.
S-483-6363
Keep up with the latest developments in

Cancer Research

The Official Journal of the American Association for Cancer Research

Subscribe to Cancer Research—the leading citation source of original studies in cancer research and cancer-related biomedical science. Issued semimonthly, Cancer Research publishes over 8,000 pages per year that keep you abreast of the most significant and timely findings in your field through the following regular features:

- **The most up-to-date articles** in basic research and clinical and epidemiological investigations by authors from the United States and more than 20 countries
- **Perspectives in Cancer Research**, in which leading investigators explore contemporary and at times controversial topics
- **Supplemental issues** developed from symposia on relevant subjects—the February 1990 Supplement features the Second Conference on Radioimmuno-detection and Radioimmunotherapy of Cancer
- **Proceedings of the American Association for Cancer Research**, a special annual issue that offers stimulating new research ideas in abstract form

Order Now!

☐ Yes, I want to keep up with the latest developments in Cancer Research. Enter my one-year subscription.

**1994 Subscription Rates:**

☐ Individual $350 ☐ Institutional $350

Add $60 for delivery outside the U.S. Subscriptions payable in advance (in US currency or equivalent) to:

WAVERLY PRESS, INC./CANCER RESEARCH
428 East Preston Street/Baltimore, MD 21202

NAME

INSTITUTION

ADDRESS

CITY/STATE/ZIP

Allow 8 weeks for receipt of first issue.
The recognition of the role of the glutathione S-transferases in the metabolism and detoxification of xenobiotic carcinogens prompts consideration of the interesting prior history of this family of enzymes. In 1965, Brian Ketterer et al. (Biochem. J., 103: 316-324, 1967) isolated a protein from rat liver that bound azo dye carcinogens. A few years later, Gerald Litwack and K. S. Morey (Biochemistry, 8: 4813-4821, 1969) and Irwin Arias et al. (Proc. Natl. Acad. Sci. USA, 64: 168-170, 1969) described proteins from the same source which bound cortisol and bilirubin as well as several drugs. Litwack and Morey showed that the cortisol-binding and the carcinogen-binding proteins were identical (Biochem. Biophys. Res. Commun., 38: 1141-1148, 1970). Ultimately, the three hepatic proteins were recognized to be identical by Litwack et al. [Nature (Lond.), 234: 466-467, 1971], who coined the term ligandin. Jakoby’s group was interested in the reaction mechanism of a diverse group of enzymes, the glutathione transferases, and purified them to homogeneity from both rat and human liver (J. Biol. Chem., 249: 7130-7148, 1974). Subsequently, Arias, Jakoby, and coworkers established the identity of ligandin with glutathione S-transferase B (Proc. Natl. Acad. Sci. USA, 71: 3879-3882, 1974), and Talalay et al. (Proc. Natl. Acad. Sci. USA, 74: 158-162, 1977) demonstrated that this transferase is identical to another enzyme, \( \Delta \)-3-ketosteroid isomerase of rat liver.

Glutathione S-transferases comprise a family of enzymes with a broad substrate specificity, which participate in a variety of detoxication processes leading to excretion of xenobiotic agents as mercapturic acids. They achieve a special significance in their increased activities in early stages of hepatocarcinogenesis, thereby serving as markers of preneoplasia in liver and other organs. Glutathione S-transferases can be induced by certain carcinogens (Ding and Pickett, J. Biol. Chem., 260: 553-559, 1985) but not by peroxisome-proliferator drugs (see Cancer Research cover, February 15, 1990). Enhanced production of the pi form characterizes many human neoplasms. Bueding et al. (Cancer Res., 38: 4486-4495, 1978) found that glutathione S-transferase was greatly elevated in liver and other tissues by butylated hydroxyanisole and ethoxyquin. They have proposed that the potent anticarcinogenic effects of these substances are due at least in part to their stimulation of glutathione S-transferase activity.


Pictured are: Gerald Litwack, lower left; W. B. Jakoby, upper left; Brian Ketterer, upper middle; Irwin Arias, upper right; and Paul Talalay, lower right.

Sidney Weinhouse